197 related articles for article (PubMed ID: 10971409)
1. Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome.
McMahon C; Smith J; Khair K; Liesner R; Hann IM; Smith OP
Br J Haematol; 2000 Aug; 110(2):461-8. PubMed ID: 10971409
[TBL] [Abstract][Full Text] [Related]
2. Central venous access device-related infections in patients with haemophilia.
Yeoh ZH; Furmedge J; Ekert J; Crameri J; Curtis N; Barnes C
J Paediatr Child Health; 2013 Mar; 49(3):242-5. PubMed ID: 23438133
[TBL] [Abstract][Full Text] [Related]
3. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland.
Vepsäläinen K; Lassila R; Arola M; Lähteenmäki P; Möttönen M; Mäkipernaa A; Riikonen P
Haemophilia; 2015 Nov; 21(6):747-53. PubMed ID: 25832453
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of infectious complications associated with central venous access devices in children with haemophilia.
Tarantino MD; Lail A; Donfield SM; Lynn H; Peddle L; Hunsberger S; Shapiro AD
Haemophilia; 2003 Sep; 9(5):588-92. PubMed ID: 14511299
[TBL] [Abstract][Full Text] [Related]
5. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.
Rodriguez V; Mancuso ME; Warad D; Hay CR; DiMichele DM; Valentino L; Kenet G; Kulkarni R
Haemophilia; 2015 Sep; 21(5):e369-74. PubMed ID: 26178581
[TBL] [Abstract][Full Text] [Related]
6. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
7. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS).
Langley AR; Stain AM; Chan A; McLimont M; Chait S; Wu J; Poon MC; Card R; Israels SJ; Laferriere N; Klaassen RJ; Rivard GE; Cloutier S; Hawes S; Feldman B; Blanchette V
Haemophilia; 2015 Jul; 21(4):469-76. PubMed ID: 26104147
[TBL] [Abstract][Full Text] [Related]
8. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
Jeng MR; O'Brien M; Wong W; Zoland J; Lea J; Tang N; Glader B
Haemophilia; 2009 Nov; 15(6):1272-80. PubMed ID: 19601989
[TBL] [Abstract][Full Text] [Related]
9. Central venous access devices in haemophilia.
Valentino LA; Ewenstein B; Navickis RJ; Wilkes MM
Haemophilia; 2004 Mar; 10(2):134-46. PubMed ID: 14962202
[TBL] [Abstract][Full Text] [Related]
10. Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications.
Abdul-Rauf A; Gauderer M; Chiarucci K; Berman B
J Pediatr Hematol Oncol; 1995 Nov; 17(4):342-5. PubMed ID: 7583391
[TBL] [Abstract][Full Text] [Related]
11. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
Komvilaisak P; Connolly B; Naqvi A; Blanchette V
Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
[TBL] [Abstract][Full Text] [Related]
12. Complications of central venous access devices in children with and without cancer.
Tobiansky R; Lui K; Dalton DM; Shaw P; Martin H; Isaacs D
J Paediatr Child Health; 1997 Dec; 33(6):509-14. PubMed ID: 9484682
[TBL] [Abstract][Full Text] [Related]
13. Complications experienced with central venous catheters in children with congenital bleeding disorders.
Collins PW; Khair KS; Liesner R; Hann IM
Br J Haematol; 1997 Oct; 99(1):206-8. PubMed ID: 9359525
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of management of CVAD occlusions.
Peng C; Monagle P; Newall F
Arch Dis Child; 2011 Sep; 96(9):885-7. PubMed ID: 21398316
[TBL] [Abstract][Full Text] [Related]
15. Use of central venous catheters in children with severe congenital coagulopathy.
Liesner RJ; Vora AJ; Hann IM; Lilleymann JS
Br J Haematol; 1995 Sep; 91(1):203-7. PubMed ID: 7577634
[TBL] [Abstract][Full Text] [Related]
16. Central venous Access device SeCurement And Dressing Effectiveness (CASCADE) in paediatrics: protocol for pilot randomised controlled trials.
Ullman AJ; Kleidon T; Gibson V; Long DA; Williams T; McBride CA; Hallahan A; Mihala G; Cooke M; Rickard CM
BMJ Open; 2016 Jun; 6(6):e011197. PubMed ID: 27259529
[TBL] [Abstract][Full Text] [Related]
17. Is Routine Preprocedural Bloodwork Needed for Elective Central Venous Access Device Removals in Children without Bleeding Dyscrasias?
Donnellan J; Smith CE; John P; Amaral JG
J Vasc Interv Radiol; 2020 Feb; 31(2):276-281.e1. PubMed ID: 31883934
[TBL] [Abstract][Full Text] [Related]
18. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial.
Svoboda P; Barton RP; Barbarash OL; Butylin AA; Jacobs BR; Lata J; Haire WD; Jaff MR; Firszt CM; Mouginis TL; Schuerr DM; Schulz GA; Schwartz LB; El-Shahawy MA
Crit Care Med; 2004 Oct; 32(10):1990-6. PubMed ID: 15483405
[TBL] [Abstract][Full Text] [Related]
19. Tunnelled central venous access devices in small children: A comparison of open vs. ultrasound-guided percutaneous insertion in children weighing ten kilograms or less.
Vierboom L; Darani A; Langusch C; Soundappan S; Karpelowsky J
J Pediatr Surg; 2018 Sep; 53(9):1832-1838. PubMed ID: 29706443
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of central venous access devices in children with haemophilia.
Upadhyaya M; Richards M; Buckham S; Squire BR
Pediatr Surg Int; 2009 Jun; 25(6):503-6. PubMed ID: 19455342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
